Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum type A2 toxin - Shionogi

Next Previous
X
Search
Drug Profile

Botulinum type A2 toxin - Shionogi

Alternative Names: 150kDa botulinum type A toxin - KM Biologics; A2NTX; Botulinum type A toxin (150kDa) - KM Biologics; LMW botulinum type A toxin; Low molecular weight botulinum type A toxin; NTX

Latest Information Update: 28 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaketsuken; University of Tokushima
  • Developer Kaketsuken; Shionogi; University of Tokushima
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Muscle spasticity
  • Discontinued Dystonia

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for clinical-Phase-Unknown development in Muscle-spasticity in Japan (Intradermal, Injection)
  • 11 Dec 2017 Discontinued - Clinical-Phase-Unknown for Dystonia in Japan (Intradermal) (Kaketsuken pipeline, December 2017)
  • 17 Dec 2007 No development reported - Clinical-Phase-Unknown for Dystonia in Japan (Intradermal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top